Doby

//Dobrinka Encheva

About Dobrinka Encheva

This author has not yet filled in any details.
So far Dobrinka Encheva has created 187 blog entries.

CytoReason uses AI to personalize #drugs, opening the door to #cancer treatments

STEWART ROGERS | APRIL 16, 2018 8:30 AM Image Credit: CytoReason   The first question most people have when talking about #artificialIntelligence is if it will help us or harm us. But in the health industry, the answer to that question is clear. Whether it is being used to identify patients at risk or interrogate #X-rays and scans to aid in [...]

By | 2018-04-24T11:57:15+00:00 April 24th, 2018|Blog|Comments Off on CytoReason uses AI to personalize #drugs, opening the door to #cancer treatments

Spotlight On Israel: Market Challenges Stunting Biopharma Growth

23 Apr 2018 | Lucie Ellis Executive Summary Scrip investigates the big issues Israel's #biopharma sector need to overcome in order to maintain momentum and achieve sustainable success. AHARON AHARON, CEO OF THE ISRAEL INNOVATION AUTHORITY. Source: Israel Innovation Authority In its 70th anniversary year, Israel can rightly celebrate the boom in its high-tech sector over the last [...]

By | 2018-04-24T11:57:16+00:00 April 24th, 2018|Blog, PR|Comments Off on Spotlight On Israel: Market Challenges Stunting Biopharma Growth

MIXiii-Biomed 2018 Early Bird Registration – one week left

1 (ONE) Week to Go… Early Bird Registration Deadline Israel remains one of the superpowers in the field of Nanotechnology, with far-reaching effects into many diverse industries, one of which is Biomedicine.  MIXiii-Biomed 2018 is ready to welcome thousands of participants from Israel and around the globe. This year, we are proud to announce, a [...]

By | 2018-04-24T11:26:06+00:00 April 23rd, 2018|News|Comments Off on MIXiii-Biomed 2018 Early Bird Registration – one week left

(Personalized medicine is approaching a major breakthrough” (Hebrew”

"הרפואה המותאמת אישית מתקרבת לפריצת דרך משמעותית" פרופ' דיוויד סידרנסקי, חוקר סרטן נודע בארה"ב ומנהל קרן השקעות הביומד בישראל (IBF), מסביר בראיון ל"גלובס" מדוע רק עכשיו הרפואה המותאמת אישית עומדת להצדיק את ההייפ שהיה סביבה לפני עשור ● סידרנסקי מגלה גם שחברת איילה פארמה, מהחברות המובילות בפורטפוליו, מתכננת הנפקה, ומפרט את מטרות הקרן: "אנחנו מחפשים [...]

By | 2018-04-17T14:39:39+00:00 April 17th, 2018|News|Comments Off on (Personalized medicine is approaching a major breakthrough” (Hebrew”

MIXiii-Biomed 2018 – Meet the Start-ups

  A world of medical innovations MEET THE START-UPS The annual 17th MIXiii-Biomed Exhibition and Conference will open its doors on 15 May 2018. Every year MIXiii-Biomed introduces to its participants start-up companies bringing the latest innovations in technology and science and will, without any doubt, help shape the future of the BIOMED industry. This year is no [...]

By | 2018-04-17T08:25:28+00:00 April 16th, 2018|News|Comments Off on MIXiii-Biomed 2018 – Meet the Start-ups

Healthy.io Brings Smartphone Urine Tests to U.S. Homes

The Israel-based startup partnered with the American National Kidney Foundation and Pennsylvania-based Geisinger Health System to offer its testing kits to U.S. patients Lilach Baumer | 19:26 15.04.18 The American National Kidney Foundation and Pennsylvania-based Geisinger Health System have partnered with Israel-based startup Healthy.io to enable smartphone-based urine tests at home. On Monday, the three will [...]

By | 2018-04-16T12:56:29+00:00 April 16th, 2018|Blog|Comments Off on Healthy.io Brings Smartphone Urine Tests to U.S. Homes

Mylan buys rights to Israel-developed Multiple Sclerosis treatment

MS drug developed by Mapi Pharma requires a once-monthly injection instead of 3 times a week By TOI STAFF 11 April 2018, 12:19 am | Times New Israel Mylan already sells a generic version of Teva Pharmaceuticals’ widely-used MS treatment, Copaxone. But, if GA Depot successfully completes its Phase III clinical trials, it will be formidable competition [...]

By | 2018-04-12T15:01:24+00:00 April 12th, 2018|Blog|Comments Off on Mylan buys rights to Israel-developed Multiple Sclerosis treatment

Medtronic Buys Medical Visualization Company Visionsense for $65 Million

The medical device developer intends to integrate Israel-based Visionsense's operations into its own activities Meir Orbach | 10:16 10.04.18 | Calcalistech Medical device maker Medtronic PLC is buying Israel-based medical visualization company Visionsense Ltd. for $65 million, two people familiar with the matter told Calcalist on condition of anonymity. Visionsense will receive an upfront payment of [...]

By | 2018-04-12T10:08:51+00:00 April 12th, 2018|Blog|Comments Off on Medtronic Buys Medical Visualization Company Visionsense for $65 Million

Israeli Startup Ayala Taking BMS Cancer Drug Into Phase II With $17m Financing

EMERGING ISRAELI BIOPHARMA FLIES FLAG FOR EX-BMS CANCER THERAPY by Phil Taylor | Apr 10, 2018 9:57am | FierceBiotech Israeli biotech Ayala Pharmaceuticals, founded last year as a development vehicle for two of Bristol-Myers Squibb’s cancer candidates, has raised $17 million in a series A financing. The new company licensed rights to BMS’s gamma secretase inhibitor BMS-906024 in December, [...]

By | 2018-04-12T10:06:08+00:00 April 11th, 2018|Blog|Comments Off on Israeli Startup Ayala Taking BMS Cancer Drug Into Phase II With $17m Financing

Israel On Quest For Digital Health Domination

10 Apr 2018 | MEDTECH NEWS by Catherine Longworth Israel has set its sights on becoming a global leader in digital health, boosted by the government's new five-year plan to invest nearly $300m to drive innovation in this space. Israel is on a mission. The self-dubbed "Start-Up Nation" has proclaimed its ambition to become the world's [...]

By | 2018-04-11T10:22:13+00:00 April 11th, 2018|PR|Comments Off on Israel On Quest For Digital Health Domination